Rituximab treatment can boost survival, slash AAV relapse rate

Rituximab treatment can boost survival, slash AAV relapse rate

In severe ANCA-associated vasculitis (AAV), rituximab may be superior to cyclophosphamide at helping people survive beyond 10 years and achieve remission, while reducing the need for standard corticosteroids. These are the findings of a Japanese real-world study that also found rituximab was not associated with any infection-related deaths,…

Fasenra linked to sustained remission in EGPA: Real-world data

Fasenra (benralizumab) provides meaningful benefits for people with eosinophilic granulomatosis with polyangiitis (EGPA), including those testing positive for self-reactive antibodies called ANCAs, according to a systematic review of real-world data. Specifically, Fasenra was associated with sustained remission rates, significant corticosteroid-sparing effects, and reductions in symptoms related to the respiratory…

A good primary care physician is crucial to my vasculitis care

When living with vasculitis, we patients often zero in on our specialists, and the list can feel endless: rheumatologists, pulmonologists, nephrologists, otolaryngologists, cardiologists, and more. But what sometimes gets lost in the shuffle is our primary care physician (PCP). As I’ve settled into a new city and searched for…

Immune pathway could be MPA biomarker, therapy target: Study

The most common types of ANCA-associated vasculitis (AAV) show distinctive activity patterns of type I interferons (IFN-I), a group of immune signaling molecules, suggesting a possible route for individualized monitoring and treatment strategies, a study reports. People with microscopic polyangiitis (MPA) and associated kidney disease had more IFN-I…

Increase in antibody levels predicts relapse risk in AAV: Study

An increase in blood levels of a self-reactive antibody called MPO-ANCA predicted the return of ANCA-associated vasculitis (AAV) symptoms within months in most patients in a Belgian study. None of the patients whose MPO-ANCA levels decreased and remained undetectable in blood experienced relapses, data showed. “Monitoring MPO-ANCA levels in…

Reduced dose of cancer drug helps AAV patients, study finds

A reduced dose of obinutuzumab, an immunosuppressant approved for certain blood cancers, safely helped most adults with ANCA-associated vasculitis (AAV) achieve sustained disease remission, while reducing their need for standard glucocorticoids. That’s according to a single-center study in China involving 12 adults with hard-to-treat AAV and four adults with…